Proxymetacaine 0.5% / Fluorescein 0.25% eye drops 0.5ml unit dose preservative free
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Proxymetacaine + Fluorescein
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Proxymetacaine + Fluorescein on the MHRA register
Minims proxymetacaine 0.5% / fluorescein 0.25% eye drops 0.5ml unit dose
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 24 studies.
Reviews & meta-analyses: 7 · 1995–2024
Showing all 24 studies, sorted by most relevant.
Fanyong Yan, Keqing Fan, Zhangjun Bai, et al.
Trends in Analytical Chemistry, 2017
Ilyse S. Kornblau, J. El-Annan
Survey of ophthalmology, 2019
- Contrast Media
- Drug Hypersensitivity
- Fluorescein Angiography
Zhen‐Hai Fu, Xiao-Jie Han, Yongliang Shao, et al.
Analytical chemistry, 2017
- Coumarins
- Cysteine
- Fluorescent Dyes
Florent Le Guern, Vanessa Mussard, A. Gaucher, et al.
International Journal of Molecular Sciences, 2020
- Hydrogen-Ion Concentration
- Biosensing Techniques
- Electrochemical Techniques
Potential of hydrogen (pH) is one of the most relevant parameters characterizing aqueous solutions. In biology, pH is intrinsically linked to cellular life since all metabolic pathways are implicated into ionic flows. In that way, determination of local pH offers a unique and major opportunity to increase our understanding of biological systems. Whereas the most common technique to obtain these data in analytical chemistry is to directly measure potential between two electrodes, in biological systems, this information has to be recovered in-situ without any physical interaction. Based on their non-invasive optical properties, fluorescent pH-sensitive probe are pertinent tools to develop. One of the most notorious pH-sensitive probes is fluorescein. In addition to excellent photophysical properties, this fluorophore presents a pH-sensitivity around neutral and physiologic domains. This review intends to shed new light on the recent use of fluorescein as pH-sensitive probes for biological applications, including targeted probes for specific imaging, flexible monitoring of bacterial growth, and biomedical applications.
Abstract licence: CC BY
F. Acerbi, M. Broggi, K. Schebesch, et al.
Clinical Cancer Research, 2017
- Fluorescent Dyes
- Surgery, Computer-Assisted
- Brain Neoplasms
A. Couturier, Pierre-Antoine Rey, A. Erginay, et al.
Ophthalmology, 2019
- Ranibizumab
- Perfusion Index
- Diabetic Retinopathy
I. Vermes, C. Haanen, H. Steffens-Nakken, et al.
Journal of immunological methods, 1995
- Apoptosis
- Diploidy
- DNA Damage
B. Ou, Maureen Hampsch-Woodill, R. Prior
Journal of agricultural and food chemistry, 2001
- Fluorescent Dyes
- Fluorescein
- Antioxidants
R. Spaide, J. Klancnik, M. Cooney
JAMA ophthalmology, 2015
- Fluorescein Angiography
- Tomography, Optical Coherence
- Capillaries
Osamu Sawada, Yusuke Ichiyama, Syunpei Obata, et al.
Graefe's Archive for Clinical and Experimental Ophthalmology, 2018
- Imaging, Three-Dimensional
- Diabetic Retinopathy
- Fluorescein Angiography
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.